1. Home
  2. NMZ vs MESO Comparison

NMZ vs MESO Comparison

Compare NMZ & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMZ
  • MESO
  • Stock Information
  • Founded
  • NMZ 2003
  • MESO 2004
  • Country
  • NMZ United States
  • MESO Australia
  • Employees
  • NMZ N/A
  • MESO N/A
  • Industry
  • NMZ Finance/Investors Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NMZ Finance
  • MESO Health Care
  • Exchange
  • NMZ Nasdaq
  • MESO Nasdaq
  • Market Cap
  • NMZ 1.2B
  • MESO 1.3B
  • IPO Year
  • NMZ N/A
  • MESO N/A
  • Fundamental
  • Price
  • NMZ $10.64
  • MESO $19.91
  • Analyst Decision
  • NMZ
  • MESO Buy
  • Analyst Count
  • NMZ 0
  • MESO 2
  • Target Price
  • NMZ N/A
  • MESO $24.00
  • AVG Volume (30 Days)
  • NMZ 356.8K
  • MESO 299.2K
  • Earning Date
  • NMZ 01-01-0001
  • MESO 08-28-2025
  • Dividend Yield
  • NMZ 5.08%
  • MESO N/A
  • EPS Growth
  • NMZ N/A
  • MESO N/A
  • EPS
  • NMZ N/A
  • MESO N/A
  • Revenue
  • NMZ N/A
  • MESO $17,198,000.00
  • Revenue This Year
  • NMZ N/A
  • MESO $288.50
  • Revenue Next Year
  • NMZ N/A
  • MESO $167.17
  • P/E Ratio
  • NMZ N/A
  • MESO N/A
  • Revenue Growth
  • NMZ N/A
  • MESO 191.39
  • 52 Week Low
  • NMZ $8.26
  • MESO $7.09
  • 52 Week High
  • NMZ $11.14
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • NMZ 67.65
  • MESO 71.01
  • Support Level
  • NMZ $10.53
  • MESO $17.10
  • Resistance Level
  • NMZ $10.64
  • MESO $18.91
  • Average True Range (ATR)
  • NMZ 0.08
  • MESO 0.49
  • MACD
  • NMZ -0.00
  • MESO 0.35
  • Stochastic Oscillator
  • NMZ 89.29
  • MESO 95.34

About NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The company's investment objectives is to provide current income exempt from regular federal income tax by investing predominantly in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories. It seeks to provide attractive monthly tax-free income, portfolio diversification and attractive after tax total returns. The fund invests in municipal securities that are exempt from federal income taxes.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: